Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Erythrocyte membrane proteins involved in deformability and aggregation are a group of structural and cytoskeletal proteins that maintain the unique biconcave shape and flexibility of red blood cells. Key components include **band 3** (an integral membrane protein), **spectrin**, **ankyrin**, and **actin**. These proteins form a network that links the plasma membrane to the underlying cytoskeleton, allowing erythrocytes to withstand mechanical stress during circulation without rupturing. The interaction between band 3 and the cytoskeleton is regulated by phosphorylation events, which modulate both deformability (the ability to change shape under stress) and aggregation (the tendency to clump together)[1][3][5]. Disruption or mutation in these proteins can lead to decreased deformability or increased fragility, contributing to diseases such as hereditary spherocytosis or elliptocytosis. While these molecules are not direct therapeutic targets like receptors or enzymes, their properties are critical for understanding red blood cell physiology in health and disease. Additional notes: This entry is considered "incorrect" as a target because it refers collectively to several structural/cytoskeletal components rather than a single molecular entity typically targeted by drugs. There is no canonical abbreviation for this group as a whole—individual components have their own standard names/abbreviations such as "band 3" or "spectrin." No approved drugs directly target these structural elements for therapeutic modulation. References used above indicate that band 3-cytoskeleton interactions play central roles in both deformability and aggregation regulation[1], with defects leading to various hematologic diseases[5].
null
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Erythrocyte membrane protein (Band 3, Spectrin, Ankyrin, Actin) (null).